Summary
36 / 100 · Bulios Score
What speaks for it
- Revenue grew by 22% a year over the last 3 years.
- Analysts expect revenue to grow by 33% this fiscal year.
What to watch
- Repaying its net debt would take 4.9 years of operating profit.
- The share price is above the Bulios Fair Price.
- It missed profit estimates 7 times in the last 8 quarters.
- It reports a profit, yet spends more cash than it brings in.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 135.6 INR for 1 INR of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (INR)
Diluted EPS (INR)
- Analyst estimate
Revenue grew by 24% a year over 5 years. Over the last 3 years it grew by 22% a year. For the next fiscal year analysts expect revenue to grow by 33%.
Growth in detailDoes it make money?
ReasonablyWhere 100 INR of revenue goes
- Cost of sales 34 INR
- Sales and administration 54 INR
- Taxes and other 7.1 INR
- Net profit 4.8 INR
Net profit, industry median (Medical - Care Facilities) 6.7 INR
Out of every 100 INR of revenue, 4.8 INR is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail